Searched for
BIOSIMILAR MEDICINES ASSOCIATION
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Dr Reddy's gets European nod for biosimilar to treat osteoporosisProlia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk ...
- Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, EvfraxyBiocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These ...
- Biocon biologics receives European Commission approval for Vevzuo, Evfraxy Denosumab biosimilars for bone diseasesBiocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars, used to trea...
- Biocon Biologics settles patent issue; paves way for launch of biosimilar product in CanadaBiocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...
- Lupin inks licensing pact with Japan-based I'rom GroupDenosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-rela...
- Biocon Q4 results: Net profit grows 105% on strong biosimilar business growthFor the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 ...
- Working with govt, key stakeholders to ensure continued supply of medicines: IPAThe Indian Pharmaceutical Alliance (IPA) and various pharma industry associations in India and other key stakeholders in the pharmaceutical...
- Indian Pharmaceutical Alliance commits to help fight Covid-19The statement further said that the alliance is working closely with the International generic and biosimilar medicines association, the WH...
- Understanding the biosimilars opportunity for Indian pharmaBiosimilars to biologic drugs are what generics are to chemical drugs.
- USFDA okays Mylan, Biocon's biosimilar of cancer drug HerceptinOgivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...
- Biocon shares gain on updates on proposed biosimilars Trastuzumab and PegfilgrastimOn the BSE, 1.61 lakh shares were traded on the counter so far in the trade.
- Big boost for Biocon as USFDA Onco committee approves company's first breast cancer biosimilar drugThe USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.
- USFDA accepts Mylan's application for proposed biosimilar TrastuzumabThis is Mylan and Biocon's "first US regulatory submission through the 351(k) pathway and reinforces the strength of collaboration."
- EMA accepts marketing application of Biocon, Mylan productMylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...
- Mylan launches breast cancer drug in IndiaDrug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.
- Indian cos will get to sell biosimilars in US market earlierDrugmakers are set to gain with US’ plan to reduce data exclusivity period to 7 years from 12 years.
Load More
